ReviewClinical epidemiology2014
Cryptococcal meningitis: epidemiology and therapeutic options.
Review in Clinical epidemiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Review of the aetiologies of central nervous system infections in Vietnam.Frontiers in public health · 2024Pooled it
- Cryptococcal antigenemia and its predictors among HIV infected patients in resource limited settings: a systematic review.BMC infectious diseases · 2020Pooled it
- Magnitude ofAfrican health sciences · 2020Pooled it
- Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda.PLoS neglected tropical diseases · 2020Trial
- Trial
- Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality.PloS one · 2018Trial
- Discovery of Novel Ligands for the Treatment of Cryptococcus neoformans Infection.Archiv der Pharmazie · 2026Article
- Clinical Characteristics and Predictors of One-Year Mortality in HIV and Non-HIV Patients with Cryptococcal Infections in a Middle-Income Setting: A Multicenter Cohort Study.Journal of fungi (Basel, Switzerland) · 2026Article
- Right parietal cryptococcoma in a young immunocompetent patient: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Neurological Infections in HIV: A Case-Based Review for Clinicians.Le infezioni in medicina · 2026Review
- Admission D-Dimer for Early Risk Stratification of in-Hospital Mortality in Adults with Non-HIV Cryptococcal Meningitis: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Clinicopathological Features, Treatment Outcome, and the Cryptococcal Antigen Latex Agglutination System Titer in Feline Cryptococcosis Treated with Amphotericin B and Fluconazole.Veterinary sciences · 2025Article
- Macropinocytosis mediates neurotropism ofResearch square · 2025Article
- Whole-genome sequencing and comparative genomic analysis ofMicrobial genomics · 2025Article
- Construction of a nomogram model based on multiple factors to differentiate cryptococcal meningitis from tuberculous meningitis in HIV-Infected patients.Scientific reports · 2025Article
- Thiazole Derivatives as Promising Candidates for Cryptococcosis Therapy.ACS infectious diseases · 2025Article
- Normal opening pressure lumbar puncture in cryptococcal meningitis complicated by a cerebral venous thrombosis: a case report and literature review.Frontiers in medicine · 2025Article
- Article
- Design of an epitope-based peptide vaccine against Cryptococcus neoformans.FEBS open bio · 2024Article
- Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cryptococcal meningitis causes morbidity and mortality worldwide. The burden of disease is greatest in middle- and low-income countries with a high incidence of human immunodeficiency virus (HIV) infection. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at risk. Treatment of cryptococcal meningitis consists of three phases: induction, consolidation, and maintenance. Effective induction therapy requires potent fungicidal drugs (amphotericin B and flucytosine), which are often unavailable in low-resource, high-endemicity settings. As a consequence, mortality is unacceptably high. Wider access to effective treatment is urgently required to improve outcomes. For human immunodeficiency virus-infected patients, judicious management of asymptomatic cryptococcal antigenemia and appropriately timed introduction of antiretroviral therapy are important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.